-transparent.png){kind=logo}
Previous studies have revealed bleomycin to be a potent base-substitution mutagen in repackaged phage lambda. In order to assess the role of apurinic/apyrimidinic (AP) sites in bleomycin-induced mutagenesis, bleomycin-damaged lambda DNA was treated with putrescine or endonuclease IV to effect cleavage of bleomycin-induced AP sites. The DNA was then packaged, the phage grown in SOS-induced E. coli, and the frequency of clear-plaque mutants in the progeny was determined. Bleomycin-induced mutagenesis was decreased approx. 2-fold by treating the DNA with putrescine, but was unaffected by endonuclease IV. The results are consistent with the production of bleomycin-induced mutation at certain AP sites having a closely opposed single-strand break, since such sites are cleaved by putrescine but not by endonuclease IV.
R J Steighner, and
L F Povirk
January 1986,
Annual review of genetics,
R J Steighner, and
L F Povirk
September 1987,
Mutation research,
R J Steighner, and
L F Povirk
July 2016,
Scientific reports,
R J Steighner, and
L F Povirk
January 1991,
Genetika,
R J Steighner, and
L F Povirk
October 2012,
Journal of the American Chemical Society,
R J Steighner, and
L F Povirk
January 1975,
Basic life sciences,
R J Steighner, and
L F Povirk
June 2023,
ACS chemical biology,
R J Steighner, and
L F Povirk
June 1998,
The Journal of biological chemistry,
R J Steighner, and
L F Povirk
May 1988,
Biochemistry,
R J Steighner, and
L F Povirk
June 1999,
Cancer research,
